History

The Lancet Oncology was launched in September, 2000, as a lively monthly journal containing reviews, opinion, and news covering international issues relevant to clinical cancer specialists worldwide. In May, 2005, the journal expanded to include original research and began publishing articles Online First prior to print publication. The journal has quickly established itself as one of the premier journals worldwide for original research, especially reports from clinical trials. Uniquely, all original research is peer-reviewed via a fast-track service, and successful papers are published within 8 weeks of submission. In 2008, the journal expanded its online presence to include regular podcasts.

In 2007, The Lancet Oncology also convened its first conference, held in Singapore, entitled Asia and Cancer Management in the 21st Century. Additionally in 2007, the journal hosted a plenary lecture at the Oncology Congress in San Francisco, CA, USA, on the topic of developmental biology, self renewal, and cancer. In subsequent years, the journal has hosted a second plenary lecture at the 2008 Oncology Congress, and the inaugural Asian Oncology Summit in 2009. In 2010, The Lancet Oncology's involvement in conferences will continue to expand with further events, including the Second Asian Oncology Summit in Bali, Indonesia.

Reputation and Impact

The Lancet Oncology has an impact factor of 13.283. The journal is currently ranked sixth out of 141 cancer journals worldwide, and is in the top 1.5% of all scientific journals, of any discipline, globally (ISI Journal Citation Reports, 2008). Articles published in The Lancet Oncology regularly receive coverage in the mainstream print, online, and broadcast media.

Coverage

The aim of The Lancet Oncology is to publish interesting, informative, and practice-changing articles on any topic connected with clinical oncology. Topics include, but are not limited to:

• Breast cancer
• Endocrine system cancer
• Gastrointestinal cancer
• Genitourinary cancer
• Gynaecological cancer
• Haematological cancer
• Head and neck cancer
• Neurooncology
• Paediatric oncology
• Thoracic oncology
• Sarcoma
• Skin cancer
• Epidemiology, cancer prevention, and cancer control
• Supportive care
• Imaging
• Health-care systems

About the Editor

Dr David Collingridge has been Editor of The Lancet Oncology since March, 2002, after 6 months in the role of Senior Editor. Prior to his appointments at The Lancet Oncology, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK.

Dr David Collingridge can be contacted at david.collingridge@lancet.com.